0001193125-26-222827
SEC filingRevenue grew 16.8% year-over-year, and operating loss improved meaningfully, but the company remains under severe liquidity pressure — management states existing resources will fund operations only to late Q3 2026 and explicitly concludes there is substantial doubt about its ability to continue as a going concern.
Management states that existing liquidity — including cash and cash equivalents as of March 31, 2026, as well as cash flow from net product revenue and license and other revenue — will enable the company to fund its current operating plans to late in the third quarter of 2026. This outlook reflects both the pace of commercial revenue generation and the timing of upcoming operational expenditures. Critically, management concludes there is substantial doubt regarding the company’s ability to continue as a going concern within one year, citing the near-term funding horizon and the absence of committed external financing beyond currently available resources.
Net income improved to -$22.4M from -$23.5M YoY, and diluted EPS improved to -$1.24 from -$2.77. The EPS improvement reflects both the narrower net loss and a change in share count, though the authoritative packet does not disclose the precise driver of the denominator shift. Notably, the improvement in net income includes non-cash items — specifically, the fair value remeasurement of embedded derivatives and liability-classified common stock warrants — which reduced reported losses without affecting cash flow.
Management highlights that positive topline data from 2026 clinical trials or submission of a supplemental New Drug Application would trigger increases in both selling, general and administrative expenses (for launch preparation) and research and development expenses (for regulatory filings). These potential inflection points remain contingent on clinical and regulatory outcomes — neither of which are assured — and underscore the company’s dependence on near-term catalysts to alter its liquidity trajectory.